PP-088 Association of Helicobacter pylori infection with gastroduodenal diseases in Nepal  by Pathak, J.L. et al.
S52 Abstracts, 4th DICID
PP-088 Association of Helicobacter pylori infection
with gastroduodenal diseases in Nepal
J.L. Pathak1 *, Y.P. Deo2, P. Deo1, S. Raj Kadel3.
1Department of Clinical Test and Diagnostics, Union
Hospital, Tongji Medical College, Huazhong University
of Science and Technology, Hubei, China, 2Department
of Clinical Pathology, Om Hospital and Research Center,
Kathmandu, Nepal, 3Department of Clinical Medicine,
Tongji Medical College, Huazhong University of Science and
Technology, Hubei, China
Background: Helicobacter pylori (H. pylori), a Gram-
negative bacteria, localizes in stomach and duodenum
causes various upper gastrointestinal (UGI) disorders,
which is more frequent in developing countries. Excessive
suppression of gastric acid is the cause of the severity of
gastritis due to H. pylori. The objective of the study was to
determine the role of H. pylori in gastroduodenal diseases
and functional dyspepsia among the Nepalese population.
Methods: A prospective study was carried at Om Hospital
and Research Center, Kathmandu, Nepal, from February
2007 to May 2008. 173 patients with dyspepsia were
consecutively examined using UGI endoscopy. Data analyzed
included demographic details, clinical indications for
the examination, endoscopic ﬁndings and results of the
histopathology for H. pylori. 61% cases were female.
Results: Out of 173 patients, 113 (65.31%) had chronic
gastritis, 43 (24.85%) had duodenal ulcer, 11 had gastric
ulcer, 2 had gastric adenoma, and remaining had no
pathology. 81 (71.68%) of chronic gastritis cases, 42 (97.67%)
of duodenal ulcer cases, 7 (63.6%) of gastric ulcer cases,
and all of 2 gastric adenoma cases had H. pylori. Overall
prevalence of H. pylori among dyspepsia patients was
76.3% (132/173) with male to female ratio1:1.23 and mean
age 41±15.2years. Among H. pylori infected 52.27% were
smokers and 26.51% were alcoholic.
Conclusion: The result showed that Nepal also has high
prevalence of H. pylori as other south Asian countries.
Previous diagnosis and treatment of H. pylori will help to
decrease mortality, morbidity of peptic ulcer, and gastric
carcinoma which are big burden (from health and economic
point of view) in a poor country like Nepal.
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Objectives: Treatment failure for Helicobacter pylori (HP)
is due to antimicrobial resistance and recrudescence.
Traditional approach with multi-antimicrobials is complex,
with long duration of therapy, resulting in poor compliance
and numerous side effects. A newer therapeutic paradigm
is evolving with shorter durations, salvage therapies, and
sequential regimens. This study utilizes an ultra-short
regimen for better compliance, minimal side effects and
similar efﬁcacy.
Methods: Seventy-ﬁve (n = 75) dyspeptic patients of diverse
ethnicity, mean age 36 years, underwent upper endoscopy
with four quadrant antro-gastric biopsies with positive
PCR and stool antigen for HP. All were randomized
into three arms: DeMAND (n = 25): Dexlansoprozole 60mg,
Moxiﬂoxacin 400mg, Amoxicillin 1g, Doxycycline 100mg daily
and Nitazoxanide 500mg BID for four days; LOAD (n = 25):
Levoﬂoxacin 250mg, Omeprazole 40mg, and Doxycycline
100mg daily, with Alinia (nitazoxanide) 500mg BID for seven
days; LAC (n = 25) with a standard regimen of Lansoprazole
15mg, Amoxicillin 1g, Clarithromycin 500mg BID for seven
days. Exclusion: active bleeding, pregnancy, antimicrobial
hypersensitivity, and use of antisecretory and antimicrobials
within eight weeks.
Results: 68/75 patients (90.7%) completed the study with
seven (9%) dropouts. Side effects were minor rash, dizziness,
bloating, diarrhea, and palpitations. The ITT analysis for
30 days post-therapy HP stool antigen test was negative in
19/25 patients (76%) for DeMAND, 22/25 (88%) for LOAD, and
18/25 (72%) for LAC, there was no signiﬁcant difference in
eradication rate amongst all groups (c2 = 2.1, p = 0.36). Per-
protocol analysis revealed no difference (c2 = 2.4, p = 0.30)
in eradication rate amongst DeMAND (19/23; 82.6%), LOAD
(22/23; 95%), or LAC (18/22; 81%).
Conclusions: The 4-day DeMAND regimen is well-tolerated
and clinically comparable to LOAD and LAC therapy for
the eradication of H. pylori. This novel ultra-short therapy
may provide an additional cost beneﬁt as well as patient
acceptance. A larger trial warrants validation.
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Background: Currently, a seven-day, triple-drug regimen
has been recommended as one of the ﬁrst-line therapies
for H. pylori management of which clarithromycin is a key
component. However, this therapy is being investigated
because of the increased eradication failures due to the
prevalence of clarithromycin resistant H. pylori infections.
The aim of this study is to compare two fast and direct
diagnostic methods to evaluate clarithromycin resistance in
gastric biopsy specimens.
Methods: This cross-sectional descriptive study was
performed on 200 antral gastric biopsy specimens
which were obtained from patients undergoing upper
gastrointestinal tract endoscopy in Hajar hospital of
Shahrekord, Iran. Initially, H. pylori strains were identiﬁed
by RUT. Then, analysis for clarithromycin resistance was
performed with speciﬁc primers HP23S1 and HP23S2 for 23S
rRNA gene and probe Pwt for clarithromycin sensitive strain
and probe P44G, P43G, P43C and P42G for A2144G, A2143G,
A2143C and A2152G mutations respectively by Real-time
PCR assay. Also, A2142G and A2143G point mutations were
detected by PCR-RFLP method.
Results: Out of 200 samples, 164 (82%) were H. pylori
positive. Overall, a clarithromycin susceptible strains were
detected in 105 (64.02%) patients and clarithromycin
resistance strains were detected in 59 (35.98%) which were
identiﬁed as 4 (2.44%) A2144G, 26 (15.85%) A2143G, 15
(9.15%) A2143C and 20 (12.19%) A2142G point mutations.
Purely resistant strains were detected in 38 (23.17%), while
a mixture of resistant and susceptible (heteroresistant)
bacterial strains were found in the remaining 16 (9.76%)
cases. Genotype of 5 (8.47%) strains were not detected.
39 (23.78%) resistant strains were detected by PCR-RFLP
method which were identiﬁed as 15 (9.15%) A2143G, 15
(9.15%) A2142G and 9 (5.49%) mix strains.
Conclusion: Results showed that Real-time PCR assay,
has enough sensitivity to simultaneously identiﬁcation of
H. pylori and clarithromycin resistance in short time.
